Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab-Reference-Cited by-同舟云学术

Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab

Published:2023-11 Issue:11 Volume:41 Page:459.e1-459.e8
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Shah Neil J.^ORCID,Sura Sneha D.,Shinde Reshma,Shi Junxin,Singhal Puneet,Perini Rodolfo F.,Motzer Robert J.

Funder

Merck

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference20 articles.

1. National Comprehensive Cancer Network. Kidney cancer version 3.2023. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Accessed November 14, 2022.

2. Renal cell carcinoma;Hsieh;Nat Rev Dis Primers,2017

3. Renal cell carcinoma: histological classification and correlation with imaging findings;Muglia;Radiol Bras,2015

4. Sorafenib for the treatment of advanced renal cell carcinoma;Kane;Clin Cancer Res,2006

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma;JAMA Network Open;2024-07-25

2. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data;International Journal of Clinical Oncology;2024-02-12

3. LRP6 is a potential biomarker of kidney clear cell carcinoma related to prognosis and immune infiltration;Aging;2024-01-15